Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20028854
Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98 20028854
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T37-p - 4E-BP1 (human)
Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease
rapamycin no change compared to control

T46-p - 4E-BP1 (human)
Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease
rapamycin no change compared to control

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 no change compared to control
rapamycin no change compared to control

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease
rapamycin no change compared to control

T24-p - FOXO1A (human)
Modsite: LPRPRSCtWPLPRPE SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): T24‑p, FOXO1A (mouse): T24‑p, FOXO1A (rat): T24‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease

S256-p - FOXO1A (human)
Modsite: sPrRrAAsMDNNskF SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): S256‑p, FOXO1A (mouse): S253‑p, FOXO1A (rat): S250‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease

T32-p - FOXO3A (human)
Modsite: QsRPRsCtWPLQRPE SwissProt Entrez-Gene
Orthologous residues
FOXO3A (human): T32‑p, FOXO3A (mouse): T32‑p, FOXO3A (rat): T32‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease

S9-p - GSK3B (human)
Modsite: SGRPRttsFAEsCkP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease

T346-p - NDRG1 (human)
Modsite: GtRsRsHtsEGtRsR SwissProt Entrez-Gene
Orthologous residues
NDRG1 (human): T346‑p, NDRG1 iso2 (human): T280‑p, NDRG1 iso3 (human): T265‑p, NDRG1 (mouse): T346‑p, NDRG1 (rat): T346‑p, NDRG1 (cow): T346‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease
rapamycin decrease

T246-p - PRAS40 (human)
Modsite: LPRPRLNtsDFQkLK SwissProt Entrez-Gene
Orthologous residues
PRAS40 (human): T246‑p, PRAS40 iso2 (human): T116‑p, PRAS40 iso3 (human): T266‑p, PRAS40 (mouse): T247‑p, PRAS40 (rat): T247‑p, PRAS40 (cow): T246‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease
rapamycin decrease

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease
rapamycin decrease

T1462-p - TSC2 (human)
Modsite: GLRPRGytISDsAPs SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioma, breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), MCF-7 (breast cell), U2OS (bone cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZD8055 decrease